10x Genomics (TXG.O) and Harvard University have reached a settlement in a patent dispute with rival Vizgen, just four days into a scheduled two-week trial, according to a filing in Delaware federal court on Thursday.
The lawsuit, which began when 10x and Harvard accused Vizgen of patent infringement related to gene analysis, has now been resolved. In response, Vizgen countersued, alleging that 10x and Harvard violated a contract with the U.S. National Institutes of Health (NIH) by monopolizing their technology.
The parties involved—10x, Harvard, and Vizgen—told the court that they would dismiss the case with prejudice, meaning that the claims cannot be refiled. Representatives from both sides expressed satisfaction with the resolution.
In 2022, 10x filed a lawsuit against Vizgen, claiming that the company had infringed on patents related to its Xenium In Situ gene-analysis platform. These patents are licensed by 10x from Harvard, which is also a plaintiff in the case.
10x and Harvard were seeking at least $9.2 million in damages, while Vizgen had requested between $91 million and $374 million in its antitrust counterclaim, according to court documents. Meanwhile, antitrust allegations against 10x and Harvard by life sciences company Bruker (BRKR.O) are still part of a separate patent lawsuit.
The case, titled 10x Genomics Inc v. Vizgen Inc, was being heard in the U.S. District Court for the District of Delaware (No. 1:22-cv-00595).